Navigation Links
NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
Date:11/12/2008

esults we announced last week for the 111 study. Both these ABPM trials suggest that naproxcinod's 24-hour blood pressure profile is improved compared to naproxen's and we are eager to receive the results of the ongoing 112 ABPM study in the coming months."

The 104 trial was an 8-week, double-blind, randomized, cross-over study, in which 131 hypertensive volunteers between 50 and 75 years of age were enrolled to receive either naproxcinod 750 mg bid for 2 weeks, followed by naproxen 500 mg bid for 2 weeks, or these compounds in the reverse order. Subjects received a 2-week placebo wash-out at the beginning of the study and between the active treatment periods. Eligible subjects were not current Non-Steroidal Anti-Inflammatory Drug (NSAID) users, had controlled hypertension, and could receive stable doses of up to 2 different classes of antihypertensive drugs.

NicOx is developing naproxcinod in late phase 3 clinical studies, which are designed to demonstrate that it is safe, well tolerated and effective for treating the signs and symptoms of osteoarthritis, in addition to having no detrimental effect on blood pressure, in contrast to traditional NSAIDs and COX-2 inhibitors. The results of the third phase 3 trial for naproxcinod (the 303 study) are expected before the end of the year and the filing of a New Drug Application (NDA) for naproxcinod with the U.S. Food and Drug Administration (FDA) is projected for mid-2009.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting N
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

679

GOOD

Page: 1 2 3

Related biology technology :

1. NicOx Reports Results for the First Three Quarters of 2008
2. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
3. NicOx Announces Departure of Damian Marron for CEO Position
4. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
5. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
6. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
7. NicOx Opens U.S. Headquarters in New Jersey
8. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
9. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
10. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
11. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Greenville, SC (PRWEB) August 22, 2014 ... that indisputable acknowledgement is a national disgrace. Furthermore, ... part in establishing the current, deplorable state of ... outlined "5 great mistakes," to merely serve as ... convey the extent of colossal failure(s) that have ...
(Date:8/21/2014)... Institute for Molecular Medicine Finland (FIMM), University of ... novel "man and machine" decision support system for ... described in PLOS One scientific journal ... computer vision algorithms similar to those used in ... the diagnostically most relevant areas. Tablet computers can ...
(Date:8/21/2014)... Ireland , August 21, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition ... 2014-2018"  report to their offering.  ... known as hormone therapy, is a means ... being produced by the body. This type ...
(Date:8/21/2014)... Rochelle, N.Y. (PRWEB) August 21, 2014 ... is the first private college in the Mid-Hudson Region ... College will now begin accepting applications from qualified “high-technology” ... , “We are very pleased to have been selected ... support Governor Cuomo’s transformative initiative to stimulate economic development ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3
... Inc., a private clinical-stage biotherapeutics company focused on the ... cancer, today announced that key data from its Phase ... along with data from other JX-594 clinical trials, will ... Cell Therapy (ASGCT) Annual Meeting taking place May 18-21, ...
... Reportlinker.com announces that a new market research ... Industrial Biotechnology China News 1104 ... the regional turbulence in Egypt and Libya areas, ... at USD102 per barrel on March 2, 2011; ...
... SHENYANG, China, May 11, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ... a leading China-based biotechnology company focused on researching, developing, ... financial results for the first quarter ended March 31, ... Financial Highlights: Total net ...
Cached Biology Technology:Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 2Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 3Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting 4Reportlinker Adds Industrial Biotechnology China News 1104 2Reportlinker Adds Industrial Biotechnology China News 1104 33SBio Inc. Announces Unaudited First Quarter 2011 Results 23SBio Inc. Announces Unaudited First Quarter 2011 Results 33SBio Inc. Announces Unaudited First Quarter 2011 Results 43SBio Inc. Announces Unaudited First Quarter 2011 Results 53SBio Inc. Announces Unaudited First Quarter 2011 Results 63SBio Inc. Announces Unaudited First Quarter 2011 Results 73SBio Inc. Announces Unaudited First Quarter 2011 Results 83SBio Inc. Announces Unaudited First Quarter 2011 Results 93SBio Inc. Announces Unaudited First Quarter 2011 Results 103SBio Inc. Announces Unaudited First Quarter 2011 Results 113SBio Inc. Announces Unaudited First Quarter 2011 Results 123SBio Inc. Announces Unaudited First Quarter 2011 Results 13
(Date:8/22/2014)... release is available in German . ... substances, in PCFs proteins are fixated in a way ... crystals. Next, the HZB and Fudan University researchers are ... as functional materials. Their findings are being published today ... 10.1038/ncomms5634). , Proteins are sensitive molecules. Everyone knows that ...
(Date:8/22/2014)... rhino reproduction in Europe highlights how hormone analysis ... Researchers from Chester Zoo, The University of Manchester ... six-year study which encompassed 90% of European population ... the research as part of her PhD at ... black rhinoceros breed well in captivity, not all ...
(Date:8/22/2014)... and can reduce free radical damage. Can ... stress? Jianbo Zhao and co-workers from the ... China discovered that green tea polyphenol effectively ... indicating green tea polyphenols play a protective ... stress. The relevant study has been published ...
Breaking Biology News(10 mins):Proteins: New class of materials discovered 2Hormone analysis helps identify horny rhinos 2
... Research (LICR) and the University of California, San Diego ... identifying functional elements in the human genome, according to ... , While the DNA sequence can identify genes (the ... fundamental questions of 'how,' 'when' and 'where' gene products ...
... be caused by hypoglycemic coma actually occurs when glucose is ... rodents led by researchers at the San Francisco VA Medical ... and may be of clinical significance for the treatment of ... cannot be immediately extrapolated to humans. , Insulin is ...
... over a scientific paper that is putting Korea's scientific ... pitted a young Korean doctor, Jeong Hwan Kim, against ... the most powerful players in the country's struggle for ... threatening to disrupt Korea's efforts to recover scientific credibility ...
Cached Biology News:Beyond the DNA: Chemical signatures reveal genetic switches in the genome 2Glucose triggers brain cell death in rats after hypoglycemic coma 2Glucose triggers brain cell death in rats after hypoglycemic coma 3Row over study puts Korea's scientific community under scrutiny again 2
... of RNase A-type ribonucleases Product Description: ,QIAGEN ... origin that binds noncovalently and inactivates a ... and C). It does not interfere with ... CL3. QIAGEN RNase Inhibitor inhibits greater than ...
...
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
... Thermus aquaticus (strain YT1) is cloned ... highly purified to produce Taq DNA ... amplification and sequence testing of DNA ... Taq DNA polymerase has been tested ...
Biology Products: